Jump to main content
Jump to site search

Issue 9, 2019
Previous Article Next Article

The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

Author affiliations

Abstract

This study was performed to investigate the effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was performed with 56 patients having T2DM and CHD. The patients were randomly divided into two groups to receive either 500 mg resveratrol per day (n = 28) or placebo (n = 28) for 4 weeks. Resveratrol reduced fasting glucose (β −10.04 mg dL−1; 95% CI, −18.23, −1.86; P = 0.01), insulin (β −1.09 μIU mL−1; 95% CI, −1.93, −0.24; P = 0.01) and insulin resistance (β −0.48; 95% CI, −0.76, −0.21; P = 0.001) and significantly increased insulin sensitivity (β 0.006; 95% CI, 0.001, 0.01; P = 0.02) when compared with the placebo. Resveratrol also significantly increased HDL-cholesterol levels (β 3.38 mg dL−1; 95% CI, 1.72, 5.05; P < 0.001) and significantly decreased the total-/HDL-cholesterol ratio (β −0.36; 95% CI, −0.59, −0.13; P = 0.002) when compared with the placebo. Additionally, resveratrol caused a significant increase in total antioxidant capacity (TAC) (β 58.88 mmol L−1; 95% CI, 17.33, 100.44; P = 0.006) and a significant reduction in malondialdehyde (MDA) levels (β −0.21 μmol L−1; 95% CI, −0.41, −0.005; P = 0.04) when compared with the placebo. Resveratrol upregulated PPAR-γ (P = 0.01) and sirtuin 1 (SIRT1) (P = 0.01) in the peripheral blood mononuclear cells (PBMCs) of T2DM patients with CHD. Resveratrol supplementation did not have any effect on inflammatory markers. Four-week supplementation of resveratrol in patients with T2DM and CHD had beneficial effects on glycemic control, HDL-cholesterol levels, the total-/HDL-cholesterol ratio, TAC and MDA levels. Resveratrol also upregulated PPAR-γ and SIRT1 in the PBMCs of T2DM patients with CHD.

Graphical abstract: The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

Back to tab navigation

Supplementary files

Article information


Submitted
20 May 2019
Accepted
07 Aug 2019
First published
08 Aug 2019

Food Funct., 2019,10, 6042-6051
Article type
Paper

The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

A. Hoseini, G. Namazi, A. Farrokhian, Ž. Reiner, E. Aghadavod, F. Bahmani and Z. Asemi, Food Funct., 2019, 10, 6042
DOI: 10.1039/C9FO01075K

Social activity

Search articles by author

Spotlight

Advertisements